Whitehawk Therapeutics develops next-generation antibody-drug conjugates for the treatment of cancer. Its three-asset portfolio targets proteins that are clinically validated and broadly expressed in lung, gynecological, and other solid tumors. The company applies advanced tumor-targeting approaches and ADC platform technologies to improve therapeutic index and stability.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -52.6 | — |
| Q3 2025 | 0 | — | -17.8 | — |
| Q4 2025 | 0 | — | -23.3 | — |
| Q1 2026 | 0 | — | -22.2 | — |
| Q2 2026 | 0 | — | -16.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Hudson Technologies, Inc. (HDSN), Paloma Acquisition Corp I (PALO), Kaltura, Inc. (KLTR), Silvaco Group, Inc. (SVCO), Sol-Gel Technologies Ltd. (SLGL), First Capital, Inc. (FCAP)